Oragenics (NYSEAMERICAN:OGEN – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.58) earnings per share for the quarter, FiscalAI reports.
Oragenics Stock Performance
Shares of NYSEAMERICAN OGEN traded up $0.01 during trading hours on Thursday, hitting $0.35. 27,673,266 shares of the stock were exchanged, compared to its average volume of 256,157. Oragenics has a 1-year low of $0.34 and a 1-year high of $1.22. The company has a market cap of $1.58 million, a PE ratio of -0.02 and a beta of 1.28. The company’s fifty day simple moving average is $0.45 and its two-hundred day simple moving average is $0.59.
About Oragenics
Oragenics, Inc. is a biotechnology company focused on developing intranasal medicines for neurological disorders. Its approach is designed to deliver drug candidates through the nasal passage directly to the brain, with the goal of addressing conditions for which conventional drug-delivery methods may be limited. The company’s lead product candidate is ONP-002, an intranasal therapy being developed for the treatment of concussion and traumatic brain injury. Oragenics has also pursued additional preclinical programs targeting neurological and neurodegenerative diseases, although the development status and scope of these programs may change as the company advances its pipeline.
Read More
- Five stocks we like better than Oragenics
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
